Good Neighbor Pharmacy Franchise Cost, Revenue & Review 2026
- Investment
- $279K – $575K
- Disclosed sales
- partial, no system average
- SBA charge-off
- Limited · 11 loans
Data from FDD filing + SBA 7(a) records
Analysis by FranchiseVerdict Research · Methodology
Good Neighbor Pharmacy is a franchise network of independently owned community pharmacies backed by distributor Cencora. Franchisees run local drugstores filling prescriptions, counseling patients, and selling retail health products while competing with chains and mail-order.
FranchiseVerdict summary · 2026
A Good Neighbor Pharmacy franchise requires a total initial investment of $279K – $575K. The 2025 FDD on file does not yield a unit-revenue figure we can publish. FranchiseVerdict grade: B (Above average), an editorial assessment, not investment advice. Run a live ROI scan →
Sources, dates and evidence
FDD issued: 2025 filing · Data extracted: · Last cited check: · Staleness risk: medium - a newer filing may exist
Evidence: strong✓ Investment (Item 7)✓ Item 19 status✓ Units and owners (Item 20)✓ SBA loan coverage✓ Litigation (Item 3)✓ Financial statements (Item 21)✓ Franchisor identityhow this is scored2 of 2 headline figures on this page cite a page of the filing.
Overview
- Investment
- $279K – $575K
- 57th pct Healthcare
- Avg gross sales
- N/A
- Combined outlet typesProjection
- Royalty
- Flat fee
- Units
- 2,361
- 80th pct Healthcare
- SBA charge-off
- N/A
Quick verdict · Healthcare · color = vs category peers
Green = favorable by >10% vs Healthcare median · No shading = within ±10% · Red = unfavorable by >10% · Source: FDD filings + SBA 7(a)
Data from public FDD filings and SBA records. Not financial advice. Methodology
Bottom line
- COSTTotal investment $279K – $575K.
- RETURNSItem 19 reports performance metrics rather than annual gross sales, so unit revenue is not directly comparable.
- RISKVerdict B (Above average), verdict score 65/100 (higher is better).
- GROWTHNegative: net -90 franchised outlets in the latest year (174 opened, 264 closed) (Item 20).
- FLAG264 units terminated last reporting year (11.2% of the system). Ask existing franchisees why.
Item 1 · who you're contracting with
The Franchisor
Corporate structure & franchisor financials
- Legal entity
- AmerisourceBergen Drug Corporation
- Parent company
- Cencora, Inc.
- FDD Item 1, page 8 of the 2025 FDD
- Predecessor
- Bergen Brunswig Drug Company
- Prior franchisor entity
- CEO title
- President and Chief Executive Officer
- Robert P. Mauch
- Incorporated in
- DE
- HQ
- 1 West First Avenue, Conshohocken, PA 19428
- Auditor
- Ernst & Young LLP
- Audited financials
- Franchisor revenue
- $321.3B
- vs $294.0B prior year
Overview
About
- CEO
- Robert P. Mauch
- Headquarters
- PA
- Founded
- 1985
- FDD year
- 2025
- States available
- 51
Can you afford it, and what does the money buy?
Entry cost runs 33% above the typical healthcare franchise.
Source: FDD 2025 · Items 5–7
FDD Item 7 · 2025 filing
Initial investment breakdown
| Cost component | Low | High |
|---|---|---|
| Working capital (3–6 mo) | $120K | $150K |
| Equipment, build-out, other | $159K | $425K |
| Total initial investment | $279K | $575K |
Source: Good Neighbor Pharmacy 2025 FDD, Items 5 and 7[2]. “Equipment, build-out, other” is computed as total minus disclosed line items above.
Item 7 · what it costs to open + operate
The Vitals
- Total investment
- $279K – $575K
- Middle of category vs category
- Liquid capital req'd
- $120K – $150K
- Bottom third — review vs category
- Franchise fee
- N/A
- Paid to franchisor at signing
- Royalty
- $599/month flat GNP Premier Fee (no percentage royalty)
- Ad fund
- No advertising fund or co-op required; franchisor not obl…
Ongoing fees · Item 6
| Fee | Amount |
|---|---|
| Royalty (flat) | $599/month GNP Premier Fee; may increase upon 120 days notice |
| Inventory (initial) | $0 – $250K |
What do units actually make?
Source: FDD 2025 · Item 19
ROI & LBO modelsSingle-unit · 25-unit portfolio · editable
No Item 19 revenue figure for Good Neighbor Pharmacy is on file. The return models need a revenue figure to start from, and the operating costs that turn gross sales into a profit are in no FDD. Enter your own and the calculator runs on your assumptions — nothing here is modelled until you do.
Returns model · single-unit ROIC
What would one Good Neighbor Pharmacy unit return on the cash you put in?
Illustrative category typicals — not sourced to any filing, survey or sample. Replace them with figures from franchisee validation calls before you rely on the output.
Unlevered ROIC · per unit
Your modelled return on total invested capital, before any debt financing.
—
An FDD discloses gross sales, not profit. We hold no sourced figure for annual revenue, royalty rate, ad fund rate, COGS, labour, rent / occupancy and other operating costs, and will not substitute an assumed one. Enter your own and the model runs on your assumptions.
These models are for research and scenario planning only. Not investment advice. Actual results depend on your specific location, management, and market conditions. Consult a franchise attorney and accountant before signing any franchise agreement.
Item 19 · Source: 2025 FDD
Financial Performance
Combines different outlet types in one figure
Not a revenue figure
- Item 19 type
- performance metrics
- Sample size
- 1,740
- vs category median 20 · large
- Reporting year
- 2025
- Fiscal year the figures cover
- Source filing
- FDD 2025
- The FDD edition these figures were read from
Compared against 162 Healthcare brands
Operator outlook
What the numbers say
Data-driven interpretation of this brand's financial disclosures, fee structure, and system trajectory.
Disclosure
Item 19 reports performance metrics rather than annual gross sales, so unit revenue is not directly comparable.
Operator retention
System contracting at -4.1% CAGR over 3 years. Investigate whether closures are franchisor-driven consolidation or franchisee exits.
Source: FDD Item 19 financial performance representations and publicly filed FDD data. Past performance is not indicative of future results. Verify all figures with the franchisor and current franchisees before making any investment decision.
vs Healthcare medians
How Good Neighbor Pharmacy Compares
Category median of published Healthcare brands that report the figure; the middle half spans the 25th to 75th percentile and n counts the brands behind it. Medians are used because a few very large systems pull an average far from the typical brand. Revenue is disclosed gross sales, not profit.
Is the system healthy?
Source: FDD 2025 · Item 20
Unit growth
Item 20 · unit dynamics
The Growth Chart
- Total units
- 2,361
- Opened
- 174
- Last reporting year
- Closed
- 264
- Terminated
- 264
- Franchisor ended the franchise (per Item 20)
- Non-renewed
- 0
- Term expired, not renewed (per Item 20)
- Turnover rate
- 12.0%
- Company-owned
- 0
- Corporate units in the system
- % franchised
- 100%
- vs corporate-owned
- Net growth (3-yr)
- -4.1%
- Net unit change over 3 years
- 3-yr CAGR
- -4.1%
- Compounded over last 3 years
Last fiscal year · Item 20 exits and transfers
- Terminated
- 264
- Not renewed
- 0
- Transferred
- 45
- Reacquired
- 0
- Franchisor bought back
- Signed, not yet open
- 0
- 0.00 per open outlet · Item 20 Table 5
- Projected new
- 230
- Franchisor's next-year forecast
Year-over-year franchised unit counts and net change. Source: FDD Item 20.
Item 20 · 24 states with active franchisees
The Territory Map
Derived from franchisee contact records. Shows states with at least one current operator. Not where the franchisor is registered to sell new units (that data is re-extracting in a future refresh).
States derived from franchisee contact records (FDD Item 20). Shows states with at least one current operator on file. Full state registration data (Item 12) will appear on a future FDD refresh.
Where the owners are · Item 20 owner list
123 current owners across 16 states; 18 former (terminated, transferred or not renewed) listed separately.
- AR 59
- AL 30
- AZ 6
- AK 5
- SC 3
- TN 3
- TX 3
- VA 3
- KY 2
- OH 2
- WA 2
- MS 1
- +4 more states
Counts only, from the list the franchisor prints in Item 20. Names and phone numbers are for your own due diligence and are not shown here.
SBA loan performance
Government records
SBA Loan Data
Aggregated from SBA 7(a) and 504 loan disclosures, public data unique to FranchiseVerdict.
- Total loans
- 11
- Loan volume
- $23.1M
- Median loan
- $1.9M
- 50th percentile
- Charge-off rate
- Limited · 11 loans
- Limited SBA coverage: 11 loans, rate hidden until 10 have resolved and loans reach 2% of franchised units
Historical SBA 7(a) lending data, not predictive of future performance. How SBA charge-off rates are calculated
- Repayment rate (PIF)
- Limited · 11 loans
- 5-yr charge-off
- Limited · 11 loans
- Loans approved 2021+
- Active lenders
- 5
- Defaults
- 0
- Typical loan rate
- 7.6%
- avg rate to borrowers
- Franchised industry avg
- 6.7%
- n=462 loans
- Jobs supported
- 262
- 1.1 per loan
- Lender concentration
- 45%
- top lender's share
Borrower mix: 0% went to startups / new businesses, 100% to established operators
Franchise vs independent — in pharmacies and drug stores, franchised businesses charge off at 6.7% vs 6.7% for independents
Top lenders financing Good Neighbor Pharmacy franchisees
Showing 3 of 5 lenders. The full breakdown — every lender, state distribution, interest rates & risk ratings — is in the SBA Lending Report below.
Explore lender portfolios on Bank Reports or regional data on State Reports.
Lender network · 7(a) + 504
SBA Lending Report
Full lending analysis for Good Neighbor Pharmacy from SBA 7(a) FOIA data.
- Principal loss rate
- 0.0%
- Avg SBA guarantee
- 77%
- Avg interest rate
- 7.59%
- Lender concentration
- 45.5%
- Job velocity
- 1.1 per $100K
- NAICS benchmark
- 5.7%
- NAICS 446110
- Jobs supported
- 262
Top SBA lendersTop lender holds 45% of loans
| # | Lender | Loans | Volume | Default % |
|---|---|---|---|---|
| 1 | First Financial Bank | 5 | $13.9M | 0.0% |
| 2 | Live Oak Banking Company | 3 | $5.7M | 0.0% |
| 3 | First Bank of the Lake | 1 | $150K | N/A |
| 4 | American Momentum Bank | 1 | $1.9M | N/A |
| 5 | Mission Valley Bank | 1 | $1.4M | N/A |
Geographic failure vector
| State | Loans | Defaults | Rate |
|---|---|---|---|
| CACalifornia | 3 | 0 | -- |
| TXTexas | 2 | 0 | 0.0% |
| ARArkansas | 1 | 0 | -- |
| GAGeorgia | 1 | 0 | -- |
| ILIllinois | 1 | 0 | -- |
| NCNorth Carolina | 1 | 0 | -- |
| OHOhio | 1 | 0 | -- |
| PAPennsylvania | 1 | 0 | 0.0% |
SBA 7(a) lending trend
Borrower profile
Source: SBA 7(a) + 504 FOIA loan-level data, matched by FranchiseVerdict
What could kill this investment?
Source: SBA 7(a) FOIA · FDD Items 3, 21
Risk analysis
FranchiseVerdict rating + FDD Items 3, 4, 8, 16, 21
Risk & Legal
Litigation (Item 3)
Subject: the franchisor is a named party (defendant).
Three disclosed matters: (1) Mullen/Omni/Sypula False Claims Act settlement ($625M); (2) National Prescription Opiate MDL litigation (various settlements including $4.3B Distributor Settlement Agreement); (3) DOJ civil complaint against Cencora/ABDC for Controlled Substances Act violations re suspicious order reporting.
Bankruptcy (Item 4)
None disclosed
Audited financials (Item 21)
Yes · Ernst & Young LLP
Franchisor revenue (Item 21)
Franchisor entity revenue (not unit-level)
Audited consolidated financial statements are those of the franchisor's parent, Cencora, Inc. (formerly AmerisourceBergen Corporation), for fiscal year ended September 30, 2025; figures originally reported in thousands. Franchisor is AmerisourceBergen Drug Corporation.
ⓘ These are the parent company's consolidated financials (the parent guarantees the franchisor), not this brand's standalone results — the figure reflects the whole corporate group, not this brand alone.
Supplier relationship · Items 8 & 16
- Franchisor sells you products: Yes
- Must buy proprietary products: Yes
- Restricted to system-approved products: No
Score breakdown · what drove the 65 / 100 verdict
- 01MINORDeclining unit count (2,361 units, -4.6% YoY) indicates contracting franchise system with potential saturation or performance issues
- 02HIGHExtensive litigation history including False Claims Act settlements, opioid distribution MDL settlements, public nuisance verdict, and DOJ Controlled Substances Act violations creates significant legal and operational risk
- 03MINORNo average revenue or net income disclosure (Item 19) prevents prospective franchisees from assessing realistic earning potential and ROI
- 04MINORUnprotected territory with $599 monthly royalty creates competitive vulnerability; franchisor can saturate your market without compensation
- 05MEDZero franchise fee indicates potential financial weakness of franchisor and limited resources for franchisee support and system development
Severity inferred from the FDD text · not a regulatory classification
What are you signing up for?
Source: FDD 2025 · Items 11, 12, 17
FDD Items 12, 15, 17 · continued from Risk & Legal
Contract & Territory Detail
| Initial term | 5 years |
|---|---|
| Renewal term | 2 years |
| Territory type | No territory protection |
| Protected territory | No |
| Exclusive territoryℹ | No |
| Online sales rightsℹ | Granted |
| Franchisor can compete | Yes |
| Hire a manager? | Allowed |
| Owner-operator | Optional |
| Right of first refusalℹ | No |
| Transfer requires consent | Yes |
| Termination notice | 60 days |
| Mandatory arbitration | No |
| Arbitration location | Conshohocken, PA (ABDC corporate headquarters) - mediation at ABDC option |
| Jury trial waiver | Yes |
| Governing law | PA |
| Litigation count | 3 |
View Item 3 litigation summary
Three disclosed matters: (1) Mullen/Omni/Sypula False Claims Act settlement ($625M); (2) National Prescription Opiate MDL litigation (various settlements including $4.3B Distributor Settlement Agreement); (3) DOJ civil complaint against Cencora/ABDC for Controlled Substances Act violations re suspicious order reporting.
Items 10, 11
Training & Operations
- Classroom training
- 0 hrs
- On-the-job training
- 0 hrs
- Training location
- None; no initial training currently offered
- Ongoing training
- Optional
- Site selection
- Franchisee
- Franchisor financing
- Not offered
- Item 10
Items 5 & 11
Franchisor Support
Item 20 · call current owners
Franchisee Contacts
141 owners to call
Name · phone · city · state. Extracted from FDD Item 20
Frequently asked questions
Frequently Asked Questions
How much does it cost to open a Good Neighbor Pharmacy franchise?
The total investment to open a Good Neighbor Pharmacy franchise ranges from $279K – $575K. This includes real estate, equipment, inventory, and working capital as disclosed in their Franchise Disclosure Document (FDD).
What do Good Neighbor Pharmacy franchise owners earn?
Item 19 of the Good Neighbor Pharmacy FDD discloses figures for part of the system but no single average across all outlets. These are gross sales figures, not profit; the Revenue section shows what the filing reports and on what basis. Item 20 of the FDD lists current and former franchisees; asking them directly is the standard way to fill this gap.
Who owns Good Neighbor Pharmacy?
Good Neighbor Pharmacy is franchised by AmerisourceBergen Drug Corporation. Its parent company is Cencora, Inc.. Source: FDD Item 1, 2025 filing.
What is Item 19 in the Good Neighbor Pharmacy FDD?
The FDD section where a franchisor may disclose financial performance of its outlets. Disclosure is optional and formats vary; figures are typically gross sales, which is revenue before expenses, not profit. FranchiseVerdict extracts these figures directly from the Good Neighbor Pharmacy FDD and qualifies whose outlets they describe.
What is Good Neighbor Pharmacy's franchise failure rate?
SBA 7(a) loan charge-off data is not available for Good Neighbor Pharmacy (fewer than 10 loans on file). Charge-off rates are one way to gauge franchise risk, but not all franchise loans go through the SBA program. We recommend reviewing turnover and closure data in the FDD and speaking with current franchisees.
How many Good Neighbor Pharmacy franchise locations are there?
As of their most recent FDD filing, Good Neighbor Pharmacy has 2,361 total units in the United States, including 2,204 franchised units and 0 company-owned units. 174 new units were opened in the latest reporting year.
Is Good Neighbor Pharmacy a good franchise to buy?
FranchiseVerdict rates Good Neighbor Pharmacy as a B-grade franchise with a verdict score of 65 out of 100 (higher is better). The grade is a deterministic score built from six weighted dimensions — financial health, unit economics, unit growth, scale, legal, and transparency — then calibrated against SBA loan charge-off rates and FDD age. Transparency is one of the six, so a filing that discloses less scores lower on that dimension than one that discloses more. Our rating is based solely on publicly available FDD and government data; we recommend speaking with current franchisees before making any investment decision. This is not investment advice.
Data sourced from public FDD filings and SBA 7(a) FOIA records. Not financial advice.
For franchisors
Are you the franchisor?
If you represent Good Neighbor Pharmacy, you can request corrections or provide updated information.
Other Healthcare franchises
Compare similar franchise opportunities in the Healthcare category
Data extracted from public FDD filings and SBA 7(a) loan disclosures (FOIA). This information is provided for research purposes only and does not constitute financial, legal, or investment advice. Verify all figures with the franchisor's current Franchise Disclosure Document before making any investment decision.